ATR and glioblastoma: When compared to berzosertib (Supplementary Figure 1), a widely used ATR inhibitor in clinical trials, gartisertib was 4-fold more potent across all glioblastoma cell lines (gartisertib median IC50 = 0.56 μM, berzosertib median IC50 = 2.21 μM).